|U.S. Chamber of Commerce 2007 Senate Scorecard description
The Chamber—a long-standing opponent of le … The Chamber—a long-standing opponent of legislation to authorize the unregulated reimportation of medicines from foreign sources—supported a compromise amendment to S. 1082, the Food and Drug Administration Revitalization Act, that would require the Secretary of Health and Human Services to certify public health and safety before allowing any reimportation of pharmaceuticals into the United States. This compromise, which was approved 49-40, prevented an amendment from being included in S. 1082 that would have allowed unregulated drug reimportation. Reimported prescription drugs raise serious concerns about drug safety and counterfeiting. While the Chamber recognizes the need to make prescription drugs more accessible, reimportation legislation could eliminate the ability of drug manufacturers to ensure the integrity of their products and could expose Americans to mislabeled, tainted, or expired medications. No reimportation provisions were included in subsequent legislation that ultimately became law. nt legislation that ultimately became law.